Clinical observation of mycophenolate mofetil combined with Budesonide enteric capsules in the treatment of high-risk progressive IgA nephropathy

SHEN Li; ZHANG Yao; XIAO Yaping; TANG Yuewu; DU Ni

doi:10.6039/j.issn.1001-0408.2026.07.17

您当前的位置：

首页 >

文章列表页 >

Clinical observation of mycophenolate mofetil combined with Budesonide enteric capsules in the treatment of high-risk progressive IgA nephropathy

更新时间：2026-07-16

- Clinical observation of mycophenolate mofetil combined with Budesonide enteric capsules in the treatment of high-risk progressive IgA nephropathy
- ZHONGGUO YAOFANG Vol. 37, Issue 7, Pages: 927-932(2026)
- 作者机构：
  
  1.重庆大学附属三峡医院药学部，重庆　404010
  2.重庆大学附属三峡医院肾病学科，重庆　404010
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.07.17
  CLC： R969.4;R692.3
- Received：13 November 2025，
  
  Revised：2026-03-13，
  
  Accepted：13 March 2026，
  
  Published：15 April 2026
- 稿件说明：
移动端阅览
沈莉,张尧,肖亚平,等.霉酚酸酯联合布地奈德肠溶胶囊治疗高风险进展IgA肾病的临床观察 [J].中国药房,2026,37(07):927-932.

SHEN Li,ZHANG Yao,XIAO Yaping,et al.Clinical observation of mycophenolate mofetil combined with Budesonide enteric capsules in the treatment of high-risk progressive IgA nephropathy[J].ZHONGGUO YAOFANG,2026,37(07):927-932.
沈莉,张尧,肖亚平,等.霉酚酸酯联合布地奈德肠溶胶囊治疗高风险进展IgA肾病的临床观察 [J].中国药房,2026,37(07):927-932. DOI： 10.6039/j.issn.1001-0408.2026.07.17.

SHEN Li,ZHANG Yao,XIAO Yaping,et al.Clinical observation of mycophenolate mofetil combined with Budesonide enteric capsules in the treatment of high-risk progressive IgA nephropathy[J].ZHONGGUO YAOFANG,2026,37(07):927-932. DOI： 10.6039/j.issn.1001-0408.2026.07.17.

摘要

目的

观察霉酚酸酯（MMF）联合布地奈德肠溶胶囊治疗高风险进展免疫球蛋白A肾病（IgAN）的临床效果。

方法

回顾性选取2024年8月1日至2025年3月1日于重庆大学附属三峡医院肾病学科就诊的150例成人高风险进展IgAN患者为研究对象，将使用MMF联合糖皮质激素者作为对照组（

＝94），使用MMF联合布地奈德肠溶胶囊者作为观察组（

＝56）。对比两组患者治疗后1、2、3、6个月的24 h尿蛋白（24 h UP）、估算肾小球滤过率（eGFR）、白蛋白（ALB）、完全缓解（CR）率及总有效率，以及治疗期间出现的不良反应。

结果

与治疗前比较，两组患者治疗后各时间点的24 h UP均显著降低（

＜0.05）、ALB均显著升高（

＜0.05），但eGFR无显著变化（

＞0.05）。观察组患者在治疗后1、2、3个月的24 h UP均显著低于对照组（

＜0.05）、ALB均显著高于对照组（

＜0.05），在治疗后6个月时上述两项指标的组间对比差异无统计学意义（

＞0.

05）；两组患者治疗后各时间点的eGFR对比差异均无统计学意义（

＞0.05）。观察组患者在治疗后1、2个月时的总有效率均显著高于对照组（

＜0.05）；两组患者在其余治疗时间点的总有效率和各时间点的CR率对比差异均无统计学意义（

＞0.05）。观察组患者皮肤异常、血糖升高及总不良反应的发生率均显著低于对照组（

＜0.05）。

结论

相较于MMF联合糖皮质激素，MMF联合布地奈德肠溶胶囊治疗高风险进展IgAN患者，能更快速地减少蛋白尿、提升血清ALB水平，显著提高治疗早期的总有效率，降低糖皮质激素相关的皮肤不良反应、血糖升高以及总体不良反应的发生率，具有更优的短期效益。

Abstract

OBJECTIVE

To observe the clinical efficacy of mycophenolate mofetil （MMF） combined with Budesonide enteric capsules in the treatment of high-risk progressive immunoglobulin A nephropathy （IgAN）.

METHODS

A total of 150 adult patients with high-risk progressive IgAN who attended the Department of Nephrology， Chongqing University Three Gorges Hospital， between August 1， 2024 and March 1， 2025 were enrolled in this study. The control group （

＝94） received MMF combined with glucocorticoid， while the observation group （

＝56） received MMF combined with Budesonide enteric capsules. The 24-hour urine protein （24 h UP）， estimated glomerular filtration rate （eGFR）， and albumin （ALB） levels of patients in both groups were compared at 1， 2， 3， and 6 months post-treatment. The complete response （CR） rate and overall response rate were calculated for both groups at 1， 2， 3， and 6 months post-treatment. Adverse reactions occurring during treatment were compared between the two groups.

RESULTS

Compared with before treatment， 24 h UP decreased significantly in both groups at different time points after treatment （

＜0.05）， and ALB increased significantly （

＜0.05）. However， there was no significant change in eGFR （

＞0.05）. The 24 h UP in the observation group at 1， 2， and 3 months after treatment was significantly lower than that of the control group （

＜0.05）， while the ALB level was significan

tly higher （

＜0.05）. However， at 6 months after treatment， there was no statistically significant difference in these two indicators between the two groups （

＞0.05）. There was no statistically significant difference in eGFR between the two groups at different time points after treatment （

＞0.05）. The overall response rates in the observation group at 1 and 2 months after treatment were significantly higher than those in the control group （

＜0.05）. There was no statistically significant difference in the overall response rate at the remaining treatment time points and the CR rate at all time points between the two groups （

＞0.05）. Patients in the observation group had significantly lower rates of skin abnormalities， elevated blood glucose， and overall adverse reactions compared with the control group （

＜0.05）.

CONCLUSIONS

Compared with MMF combined with glucocorticoids， MMF combined with Budesonide enteric capsules for the treatment of high-risk progressive IgAN patients can reduce proteinuria and improve serum ALB levels more quickly， significantly increase the early overall response rate， and significantly reduce glucocorticoid-related skin adverse reactions， blood glucose elevation， and the overall incidence of adverse reactions， demonstrating a better short-term benefits.

关键词

Keywords

references

FLOEGE J ， BERNIER-JEAN A ， BARRATT J ， et al . Treatment of patients with IgA nephropathy：a call for a new paradigm [J ] . Kidney Int ， 2025 ， 107 （ 4 ）： 640 - 651 .

JOHER N ， GOSSET C ， GUERROT D ， et al . Immunoglobulin A nephropathy in association with inflammatory bowel diseases：results from a national study and systematic literature review [J ] . Nephrol Dial Transplant ， 2022 ， 37 （ 3 ）： 531 - 539 .

RAJASEKARAN A ， GREEN T J ， RENFROW M B ， et al . Current understanding of complement proteins as therapeutic targets for the treatment of immunoglobulin A nephropathy [J ] . Drugs ， 2023 ， 83 （ 16 ）： 1475 - 1499 .

FLOEGE J ， RAUEN T ， TANG S C W . Current treatment of IgA nephropathy [J ] . Semin Immunopathol ， 2021 ， 43 （ 5 ）： 717 - 728 .

LAFAYETTE R ， KRISTENSEN J ， STONE A ， et al . Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy （NefIgArd）：2-year results from a randomised phase 3 trial [J ] . Lancet ， 2023 ， 402 （ 10405 ）： 859 - 870 .

BARRATT J ， LAFAYETTE R ， KRISTENSEN J ， et al . Results from part A of the multi-center，double-blind， randomized，placebo-controlled NefIgArd trial，which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy [J ] . Kidney Int ， 2023 ， 103 （ 2 ）： 391 - 402 .

HOU F F ， XIE D ， WANG J ， et al . Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy：a randomized clinical trial [J ] . JAMA Netw Open ， 2023 ， 6 （ 2 ）： e2254054 .

胡晓磊，张桂芬，郭庆寅 . 基于肠-肾轴机制对IgA肾病靶向治疗的研究进展 [J ] . 宁夏医科大学学报， 2022 ， 44 （ 11 ）： 1176 - 1181 .

LEVIN A ， AHMED S B ， CARRERO J J ， et al . Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease：known knowns and known unknowns [J ] . Kidney Int ， 2024 ， 105 （ 4 ）： 684 - 701 .

中国IgA肾病协作组（IIgANN-China）科学委员会，中华预防医学会肾脏病预防与控制专业委员会 . 中国成人IgA肾病及IgA血管炎肾炎临床实践指南：2025 [J ] . 中华内科杂志， 2025 ， 64 （ 10 ）： 918 - 944 .

TRIMARCHI H ， BARRATT J ， CATTRAN D C ， et al . Oxford classification of IgA nephropathy 2016：an update from the IgA Nephropathy Classification Working Group [J ] . Kidney Int ， 2017 ， 91 （ 5 ）： 1014 - 1021 .

BARRATT J ， KRISTENSEN J ， PEDERSEN C ， et al . Insights on Nefecon ® ，a targeted-release formulation of budesonide and its selective immunomodulatory effects in patients with IgA nephropathy [J ] . Drug Des Devel Ther ， 2024 ， 18 ： 3415 - 3428 .

SELVASKANDAN H ， JHAVERI K D ， RIZK D V . Primary IgA nephropathy：new insights and emerging therapies [J ] . Adv Kidney Dis Health ， 2024 ， 31 （ 3 ）： 180 - 193 .

QI F F ， ZENG H Q ， ZHANG J J . Targeted-release budesonide：a comprehensive review on its potential in IgA nephropathy [J ] . Heliyon ， 2025 ， 11 （ 4 ）： e42729 .

LE STANG M B ， GLEESON P J ， DAHA M R ， et al . Is complement the main accomplice in IgA nephropathy? From initial observations to potential complement-targeted therapies [J ] . Mol Immunol ， 2021 ， 140 ： 1 - 11 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

2005－2014年我国基本药物不良反应文献计量学分析

银屑胶囊联合复方氟米松软膏治疗寻常型银屑病的临床观察

4种第二代抗精神病药物治疗精神分裂症急性期的临床观察

阿法骨化醇辅助治疗小儿毛细支气管炎的临床观察

某院2013－2015年替加环素使用安全性分析

Related Author

LIU Wei

ZHANG Jinli

ZHANG Caiyun

ZHAO Liling

WANG Huiling

ZHAO Ruixia

WANG Jing

YANG Jing

Related Institution

No data

⁰